Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms in Cetuximab Activity Used in Palliative Treatment of Upper Aerodigestive Tract Tumours
Hypothesis:
Cetuximab, an anti-EGFR antibody, is used with radiotherapy in the treatment of locally
advanced and inoperable upper aerodigestive tract cancers. Actually, no predictive
biomarkers of Cetuximab antitumor activity are known in this setting. It has been shown
recently that FCγRIIIA and FCγRIIA receptor polymorphisms played a role in antitumor
activity of trastuzumab and cetuximab.
We therefore hypothesized that FCγRIIIA and FCγRIIA receptor polymorphisms may play a
predictive role in Cetuximab effectiveness in upper aerodigestive tract cancers with
recurrence or metastatic disease that make them inaccessible to loco regional treatment.
This study is a multicentre prospective pharmacogenetic observational study, conducted on
locally advanced and inoperable upper aerodigestive tract cancers.
Observational
N/A
The main objective is to evaluate the role of FCGR3A and FCGR2A receptor polymorphism in cetuximab and chemotherapy response, in patients with recurrent or metastatic squamous cell carcinomas of the upper aero-digestive tract
The main objective is to evaluate the role of FCGR3A and FCGR2A receptor polymorphism in cetuximab and chemotherapy response, in patients with recurrent or metastatic squamous cell carcinomas of the upper aero-digestive tract
Proportion of patients with positive response to treatment at 4 months
No
ROBERT Jacques, PU-PH
Principal Investigator
Institut Bergonié
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
IB2009-24
NCT01827956
October 2009
June 2011
Name | Location |
---|